Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Previous Hold Today ABUS ranks #2017 as HOLD CANDIDATE #2017 Next Hold

ABUS stock forecast Arbutus Biopharma Corporation

ABUS stock forecast

Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) EXACT Sciences Corporation (NASDAQ: EXAS ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 12) Acorda Therapeutics Inc (NASDAQ: ACOR ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Minerva Neurosciences Inc (NASDAQ: NERV ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) NextCure Inc (NASDAQ: NXTC ) Novavax, Inc. (NASDAQ: NVAX ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obseva SA (NASDAQ: OBSV ) RA Medical Systems Inc (NYSE: RMED ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sierra Oncology Inc (NASDAQ: SRRA ) Unum Therapeutics Inc (NASDAQ: UMRX ) Zomedica Pharmaceuticals Corp (NYSE: ZOM ) Stock In Focus Savara's Pulmonary Disease Drug Does Not Meet Primary Endpoint In Late-stage Study Savara Inc (NASDAQ: SVRA ) said a Phase 3 study dubbed IMPALA that evaluated its …

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 5) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(moved in sympathy with its rival, which has a competing drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Harvard Bioscience, Inc.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity …

Read more

WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus' President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference – New York Monday, May … Full story available on Benzinga.com

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: BSGM ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 8) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aquestive Therapeutics Inc (NASDAQ: AQST )(reacted to first-quarter results) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Flexion Therapeutics Inc (NASDAQ: FLXN ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Opko Health Inc. (NASDAQ: OPK )(reacted to Q1 results) Osmotica Pharmaceuticals PLC (NASDAQ: OSMT ) Retrophin Inc (NASDAQ: RTRX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Sensus Healthcare Inc (NASDAQ: SRTS ) Stock In Focus Novartis to Buy Dry Eye Disease Drug From Takeda For $3.4B Novartis AG (NYSE: NVS ) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to acquire the assets associated with Xildra, chemically lifitefgrast ophthalmic solution, 5 percent worldwide for a $3.4 billion payment upfront and potential milestone payments up to $1.9 billion.

Read more

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Pam Murphy - IR Mark Murray

Read more

Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Read more

WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 6, 2019. The schedule for the press release and conference call/webcast are as follows: • Q1 2019 Press Release: May 6, 2019 at 4:00 p.m. ET

Read more

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics Inc, (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 22) Achaogen Inc (NASDAQ: AKAO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Zafgen Inc (NASDAQ: ZFGN ) Stock In Focus Novartis Reports Strong Quarterly Results, Raises FY19 Core Operating Income Guidance Novartis AG (NYSE: NVS ) reported strong first-quarter results, with 2 percent net sales growth, thanks to 11 percent volume growth mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. Core operating income climbed 9 percent. The company expects net sales for 2019 to grow in mid-single digit in constant currency, with innovative medicines growing in mid-single digits and Sandoz generic business likely showing flat growth.

Read more

In trying to determine the current valuation of Hydrogenics Corporation (NasdaqGM:HYGS) shares, we note that the Book to Market ratio of the shares stands at 0.072804. It’s commonly accepted that a

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank